Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis (Q36150612)

12 August 2017

1 reference

title

Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis (English)

1 reference

12 August 2017

1 reference

3

Paul P Tak

1 reference

12 August 2017

Jasper J Haringman

1

1 reference

PubMed ID

15934868

12 August 2017

Roos L Oostendorp

series ordinal

2

1 reference

PubMed ID

15934868

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

1 reference

12 August 2017

10

1 reference

12 August 2017

2

1 reference

12 August 2017

299-310

1 reference

The epidemiology of rheumatoid arthritis

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Macrophages in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

New drugs for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Infection complications associated with the use of biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Lymphocyte homing and homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Cell-cell interactions in synovitis. Endothelial cells and immune cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Chemokines and cell migration in secondary lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Chemokines--chemotactic cytokines that mediate inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Chemokines in joint disease: the key to inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Chemokines: immunology's high impact factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Abandoned therapies and unpublished trials in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Chemokine blockade: a new era in the treatment of rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

RANTES and MCP-3 antagonists bind multiple chemokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Enhanced pulmonary allergic responses to Aspergillus in CCR2-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

CXCR3 is induced early on the pathway of CD4+ T cell differentiation and bridges central and peripheral functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

Pursuit of optimal outcomes in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

CCR5 is characteristic of Th1 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.2.299

10.1517/14728214.10.2.299

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15934868